Vicore to Participate in the Van Lanschot Kempen Life Sciences Conference

STOCKHOLM, SE / ACCESS Newswire / March 28, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, …
Jetzt den vollständigen Artikel lesen